Explore

Rapid Read Rapid Read
Amylyx Pharmaceuticals Highlights Post-Bariatric Hypoglycemia Research at ENDO 2026

Amylyx Pharmaceuticals Highlights Post-Bariatric Hypoglycemia Research at ENDO 2026

Amylyx Pharmaceuticals has announced its participation in the Endocrine Society's Annual Meeting (ENDO 2026) with two poster presentations. The presentations focus on post-bariatric hypoglycemia (PBH), a condition affecting individuals who have undergone bariatric surgery. The first presentation examines the healthcare burden and quality of life impacts of PBH in the U.S., while the second discusses the design of the Phase 3 LUCIDITY trial for avexitide, a GLP-1 receptor antagonist being developed to treat PBH. Avexitide has shown promise in reducing hypoglycemic events in clinical trials and has received several FDA designations, including Breakthrough Therapy and Orphan Drug status.
Trendline Trendline
Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference

Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference

Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference
Rapid Read Rapid Read
Corcept Therapeutics Presents Data on Cortisol Modulation for Type 2 Diabetes at ADA

Corcept Therapeutics Presents Data on Cortisol Modulation for Type 2 Diabetes at ADA

Corcept Therapeutics Incorporated has presented new data from its CATALYST and MOMENTUM trials at the American Diabetes Association's 86th Scientific Sessions. The data highlights the role of hypercortisolism in difficult-to-control type 2 diabetes and resistant hypertension, and the potential benefits of cortisol modulation treatment. The CATALYST trial screened over 1,000 patients with difficult-to-control type 2 diabetes, finding that 24% had hypercortisolism. Patients treated with Korlym showed significant improvements in metabolic parameters, including reductions in hemoglobin A1c, body weight, and waist circumference. The MOMENTUM trial also found a high prevalence of hypercortisolism in patients with resistant hypertension.
Rapid Read Rapid Read
Altesa BioSciences Unveils Promising Phase 2 Vapendavir Results for COPD Patients at ASM Conference

Altesa BioSciences Unveils Promising Phase 2 Vapendavir Results for COPD Patients at ASM Conference

Altesa BioSciences, a clinical-stage pharmaceutical company, presented new findings at the 2026 American Society for Microbiology (ASM) Microbe Conference, highlighting the potential of vapendavir, an investigational oral rhinovirus capsid inhibitor. The Phase 2a challenge study demonstrated that vapendavir significantly reduced inflammatory response and viral load in COPD patients infected with rhinovirus. This development is crucial as rhinovirus is responsible for about 50% of acute COPD exacerbations, which lead to increased morbidity and mortality. The study showed that vapendavir treatment reduced key inflammatory mediators, such as IFN-α2a, IP-10, and IL-29, compared to placebo. The company has also initiated the Phase 2b CARDINAL clinical trial to further assess vapendavir's efficacy in improving respiratory symptoms and maintaining lung function in COPD patients.
Trendline Trendline
Verdiva Bio Unveils Promising Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio Unveils Promising Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio Unveils Promising Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions
Trendline Trendline
FDA Approval Pending for CXU™ Gel as Zai Lab Secures Chinese Approval for TIVDAK®

FDA Approval Pending for CXU™ Gel as Zai Lab Secures Chinese Approval for TIVDAK®

FDA Approval Pending for CXU™ Gel as Zai Lab Secures Chinese Approval for TIVDAK®
Trendline Trendline
Eli Lilly's Retatrutide Shows Promising Results in Obesity and Related Conditions

Eli Lilly's Retatrutide Shows Promising Results in Obesity and Related Conditions

Eli Lilly's Retatrutide Shows Promising Results in Obesity and Related Conditions
Trendline Trendline
Seaport Therapeutics Advances GlyphAgo with Positive Phase 1 Trial Results for Anxiety Treatment

Seaport Therapeutics Advances GlyphAgo with Positive Phase 1 Trial Results for Anxiety Treatment

Seaport Therapeutics Advances GlyphAgo with Positive Phase 1 Trial Results for Anxiety Treatment
Rapid Read Rapid Read
Study Shows Apitegromab Preserves Lean Mass During Weight Loss in U.S. Trial

Study Shows Apitegromab Preserves Lean Mass During Weight Loss in U.S. Trial

A recent phase 2 trial conducted across seven sites in the United States has demonstrated that apitegromab significantly preserves lean mass during weight loss induced by tirzepatide. The trial, known as EMBRAZE, was a randomized, double-blind, placebo-controlled study involving adults with specific body mass index (BMI) criteria. Participants were administered apitegromab or a placebo alongside tirzepatide, an incretin mimetic therapy, over a 24-week period. The study found that those receiving apitegromab retained 54.9% more lean mass compared to the placebo group, with lean mass loss being significantly lower in the apitegromab group. The trial also reported that the total body weight loss was similar between both groups, but the composition of the weight loss differed, with the apitegromab group losing a larger proportion of fat mass.
Trendline Trendline
IntraBio Submits Application to European Medicines Agency for AQNEURSA® to Treat Ataxia-Telangiectasia

IntraBio Submits Application to European Medicines Agency for AQNEURSA® to Treat Ataxia-Telangiectasia

IntraBio Submits Application to European Medicines Agency for AQNEURSA® to Treat Ataxia-Telangiectasia
Rapid Read Rapid Read
Altesa BioSciences Unveils Promising Phase 2 Vapendavir Study Results for COPD Treatment

Altesa BioSciences Unveils Promising Phase 2 Vapendavir Study Results for COPD Treatment

Altesa BioSciences, a clinical-stage pharmaceutical company, presented new findings at the 2026 American Society for Microbiology (ASM) Microbe Conference, highlighting the potential of vapendavir, an investigational oral rhinovirus capsid inhibitor. The Phase 2a challenge study demonstrated that vapendavir significantly reduced inflammatory responses and viral loads in COPD patients infected with rhinovirus. This development is crucial as rhinovirus is responsible for about 50% of acute COPD exacerbations, yet no approved treatment exists. The study showed that vapendavir treatment reduced key inflammatory mediators, such as IFN-α2a, IP-10, and IL-29, compared to placebo. The company has also initiated the Phase 2b CARDINAL clinical trial to further assess vapendavir's efficacy in improving respiratory symptoms and maintaining lung function in COPD patients.
Trendline Trendline
Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study